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Dermatoses of Pregnancy - Clues to Diagnosis, Fetal 
Risk and Therapy
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Department of Dermatology, Medical University of Graz, Graz, Austria
The specific dermatoses of pregnancy represent a hetero-
geneous group of pruritic skin diseases that have been 
recently reclassified and include pemphigoid (herpes) 
gestationis, polymorphic eruption of pregnancy (syn. pruritic 
urticarial papules and plaques of pregnancy), intrahepatic 
cholestasis of pregnancy, and atopic eruption of pregnancy. 
They are associated with severe pruritus that should never be 
neglected in pregnancy but always lead to an exact work-up 
of the patient. Clinical characteristics, in particular timing of 
onset, morphology and localization of skin lesions are 
crucial for diagnosis which, in case of pemphigoid 
gestationis and intrahepatic cholestasis of pregnancy, will be 
confirmed by specific immunofluorescence and laboratory 
findings. While polymorphic and atopic eruptions of 
pregnancy are distressing only to the mother because of 
pruritus, pemphigoid gestationis may be associated with 
prematurity and small-for-date babies and intrahepatic 
cholestasis of pregnancy poses an increased risk for fetal 
distress, prematurity, and stillbirth. Corticosteroids and 
antihistamines control pemphigoid gestationis, polymor-
phic and atopic eruptions of pregnancy; intrahepatic 
cholestasis of pregnancy, in contrast, should be treated with 
ursodeoxycholic acid. This review will focus on the new 
classification of pregnancy dermatoses, discuss them in 
detail, and present a practical algorithm to facilitate the 
management of the pregnant patient with skin lesions. (Ann 
Dermatol 23(3) 265∼275, 2011)
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INTRODUCTION
Complex endocrinologic, immunologic, metabolic and 
vascular changes associated with pregnancy may influ-
ence the skin in various ways. Skin findings in pregnancy 
can roughly be classified as physiologic skin changes, 
alterations in pre-existing skin diseases, and the specific 
dermatoses of pregnancy. Physiologic skin changes in 
pregnancy include changes in pigmentation, alterations of 
the connective tissue, vascular system, and endocrine 
function as well as changes in hair and nails (Table 1)
1. 
Pregnancy is also known to influence the course of 
pre-existing skin diseases in both positive and negative 
ways
2. A typical example is psoriasis, a classical Th1- 
associated disease, which often improves in pregnancy, 
only to worsen after delivery. A special case in this 
context is impetigo herpetiformis, which today is regarded 
as a variant of generalized pustular psoriasis presenting in 
pregnancy, accompanied by systemic signs such as fever, 
chills, vomiting, diarrhea and tetanic seizures due to 
hypocalcemia. Diseases primarily associated with a 
Th2-immune response, such as lupus erythematosus and 
other autoimmune dermatoses, in contrast, character-
istically deteriorate during pregnancy and improve after 
delivery. This is thought to be due to a temporary 
imbalance that develops between the differential cytokine 
secretion profiles and the preferential cellular or humoral 
dominated Th1 and Th2 mediated immune responses in 
order to prevent rejection of the fetus. Another disease 
typically affected in its course by pregnancy is acne, 
which most often improves, but can also be quite CM Ambros-Rudolph
266 Ann Dermatol
Table 1. Physiologic skin changes in pregnancy
1
Physiologic skin changes in pregnancy
Pigmentation
  Hyperpigmentation (diffuse with accentuation Increased hormone levels (estrogen, progesterone, MSH) lead to
   of areolae mammae and linea nigra)  hyperpigmentation (by up to 90% of pregnant women) and
 melasma (70%). 
  Melasma Aggravating factors: dark skin, UV exposition.
Connective tissue
  Striae distensae Occur in up to 90% of patients, probably combined effects of genetic
predisposition, abdominal distension and hormonal factors.
Vascular system
  Edema Weight gain, redistribution of volume and hormonal factors lead
  Varicosities/hemorrhoids   to edema and varicosities and to formation of new vessels.
  Spider angiomas, teleangiectasia   Main manifestation in the third trimester, usually reversible after
  Palmar erythema  delivery. 
  Gingiva hyperemia and hyperplasia
  Pyogenic granuloma
Glandular function
  Increased eccrine gland function (except palms) Increased incidence of milaria, hyperhidrosis and dyshidrotic
  Decreased apocrine gland function   eczema on the one hand and improvement of hidradenitis
  Disturbed sebaceous gland function  suppurativa on the other. Data on sebaceous gland activity
   ( acne gravidarum, Montgomery glands)  (increased?) contradictory. 
Hair
  Hypertrichosis Prolongation of anagen phase leads to hypertrichosis during
  Postpartal telogen effluvium  pregnancy, synchronized transition into the telogen phase later
  Postpartal androgenetic alopecia (rare; typically  to postpartal effluvium.
   “male-pattern”)  Normalization within 6∼12 months.
Nails
  Increased brittleness Entirely unspecific and reversible. 
  Distal onycholysis
  Subungual hyperkeratoses
  Transverse grooving
tenacious (“acne gravidarum”). Nevi tend to darken and 
enlarge, especially on the abdomen and breasts. The 
assumption that pregnancy has deleterious effects on the 
course of melanoma has not been substantiated; however, 
diagnostic and therapeutic decisions are often delayed in 
pregnancy leading to a more advanced tumor stage and 
hence worse prognosis.
The specific dermatoses of pregnancy represent a hetero-
geneous group of severely pruritic inflammatory derma-
toses associated exclusively with pregnancy and/or the 
immediate postpartum period. The rarity of these diseases, 
their variable clinical morphology, the lack of unequivocal 
diagnostic tests (with the exception of immunofluore-
scence in pemphigoid gestationis) as well as limited 
treatment options have led to confusing terminologies and 
have made their management difficult over decades. This 
article addresses the specific dermatoses of pregnancy in 
particular as a new classification has been recently est-
ablished based on the results of a retrospective two-centre 
study on more than 500 pregnant patients
3.
HISTORICAL BACKGROUND
The first specific dermatosis of pregnancy reported was 
pemphigoid gestationis, which Milton described in 1872 
under the name herpes gestationis
4. The term “herpes” 
referred to the characteristic “creeping” blister formation. 
Only after the introduction of immunofluorescence micro-
scopy and the discovery of specific linear complement 
deposition along the dermo-epidermal junction zone (DEJ) 
in 1973 could this disease entity be differentiated from the 
other dermatoses of pregnancy. In 1904 Besnier described 
another pregnancy-related disease which he termed 
prurigo gestationis
5. The original description as well as 
illustration resemble today’s picture of atopic dermatitis; 
of interest, at that time, what we define today as atopic 
dermatitis was known as prurigo. Costello (1941) employ-
ed this term and designated all pregnancy-related derma-
toses which were not herpes gestationis as prurigo 
gestationis of Besnier and reported an incidence of 2%
6. 
In the further course of time the disease was also referred 
to as early onset prurigo of pregnancy or prurigo of pre-
gnancy
7. Bourne (1962) described a further pregnancy- 
related dermatosis under the name toxemic rash of Dermatoses of Pregnancy
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Table 2. Classification of the specific dermatoses of pregnancy
3
Classification Synonyms
Pemphigoid gestationis* Herpes gestationis
†
Polymorphic eruption of pregnancy* Pruritic urticarial papules and plaques of pregnancy (PUPPP)
†
Toxaemic rash of pregnancy
Late onset prurigo of pregnancy
Toxic erythema of pregnancy
Intrahepatic cholestasis of pregnancy Cholestasis of pregnancy
†
Pruritus/Prurigo gravidarum
Obstetric cholestasis
Jaundice of pregnancy
Atopic eruption of pregnancy Prurigo of pregnancy*
†
Prurigo gestationis
Early onset prurigo of pregnancy
Papular dermatitis of pregnancy
Pruritic folliculitis of pregnancy*
Eczema in pregnancy
Previous classifications by Holmes & Black*
13 and Shornick
†15.
Table 3. Significant differences in the clinical characteristics among the various pregnancy dermatoses in a retrospective two-center
study (n=401)
3
PG (n=21) PEP (n=109) ICP (n=15) AEP (n=256)
Primiparous women, % 48 73
a  47 44
Multiple pregnancies, %  0 16
a   0 1
Identical skin lesions in previous pregnancies, %*  9 7   88
b 34
Early presentation (＜third trimester), % 29 3  20 75
c
Average begin±SD (span), week of gestation
† 28±7 (14∼38) 34±5 (17∼41) 30±5 (24∼36) 18±9 (2∼39)
c
Location: abdominal involvement, % 95
d 98
d  36 68
Main symptom: pruritus alone, %  0 0 100  0
Morphology: secondary skin lesions exclusively, %  0 0 100  0
PG: pemphigoid gestationis, PEP: polymorphic eruption of pregnancy, ICP: intrahepatic cholestasis of pregnancy, AEP: atopic eruption
of pregnancy, SD: standard deviation.
pregnancy, which appears on the abdomen often of small 
women with excessive weight gain and prominent striae, 
corresponding to today’s polymorphic eruption of pre-
gnancy
8. Other synonyms followed such as late onset 
prurigo of pregnancy, toxic erythema of pregnancy and 
pruritic urticarial papules and plaques of pregnancy 
(PUPPP)
7,9,10. Also in 1962, Spangler et al. described an 
entity whose existence is rightly questioned today. He 
differentiated a papular dermatitis from prurigo gesta-
tionis, which is clinically similar, on the grounds of 
biochemical alterations (raised levels of β-HCG in urine, 
lowered plasma cortisol levels) and reported a drama-
tically increased fetal death rate (early miscarriage and 
miscarriage in previous pregnancies were included!)
11. In 
over 40 years, with the exception of one further case 
report by the same authors, no further case corresponding 
to the original description has surfaced. Even a recent 
large prospective study with extensive laboratory analyses 
could not detect a manifestation corresponding to “pap-
ular dermatitis”
12. The first simplified classification of 
dermatoses of pregnancy was presented by Holmes et al. 
in 1982 and included pemphigoid gestationis, poly-
morphic eruption of pregnancy and prurigo of pregnancy
9. 
One year later they added a further dermatosis, pruritic 
folliculitis of pregnancy
13,14. Whereas in the USA the 
terms herpes gestationis and PUPPP are still preferred, in 
Europe the names pemphigoid gestationis (points to the 
autoimmune pathogenesis and avoids association with 
herpes virus) and polymorphic eruption of pregnancy 
(points to the morphological spectrum) are widely 
accepted. The classification of Holmes and Black stood 
the test of time for two decades; in 1998 Shornick 
proposed a further adaptation
15. He postulated that 
folliculitis of pregnancy was not an entity on its own but 
belonged to the spectrum of prurigo of pregnancy. He 
further introduced intrahepatic cholestasis of pregnancy 
into the classification of specific dermatoses of pregnancy. 
This disease had previously not appeared in the classifi-
cation, as it displays only secondary skin changes. It 
seems sensible to include it in such as classification, as it CM Ambros-Rudolph
268 Ann Dermatol
is an important differential diagnostic consideration asso-
ciated with potential fetal risk which can increase if the 
diagnosis is delayed or overlooked. Whereas pemphigoid 
gestationis, polymorphic eruption of pregnancy and 
intrahepatic cholestasis of pregnancy are accepted as 
independent entities, prurigo of pregnancy according to 
Holmes and Black as well as to Shornick is included only 
as a questionable independent entity. Even though it has 
been repeatedly suggested since the first description by 
Besnier that there might be a link to atopy, Holmes and 
Black were the first to postulate that it might merely be the 
result of pruritus in atopic pregnant women
13. In a recent 
retrospective study on over 500 pregnant patients with 
pruritus, we were able to demonstrate conspicuous over-
laps in clinical presentation and histopathology between 
female patients with atopic dermatitis, prurigo of pre-
gnancy and pruritic folliculitis of pregnancy (together 50% 
of our patient collective), thus leading us to group them 
together under the term atopic eruption of pregnancy
3. 
This results in a new classification of specific dermatoses 
of pregnancy as follows: pemphigoid gestationis, poly-
morphic eruption of pregnancy, intrahepatic cholestasis of 
pregnancy, and atopic eruption of pregnancy (Table 2, 3).
PEMPHIGOID GESTATIONIS (SYNONYM: 
HERPES GESTATIONIS)
Pemphigoid gestationis is a rare, self-limited autoimmune 
bullous disorder that presents mainly in late pregnancy or 
the immediate postpartum period but can appear in any of 
the three trimesters. Beyond pregnancy it can also very 
rarely occur in association with trophoblastic tumors 
(choriocarcinoma, hydatidiform mole). Its incidence varies 
from 1:2.000 to 1:50.000∼60.000 pregnancies depend-
ing on the prevalence of the HLA-haplotypes DR3 and 
DR4
16. There is also an increased risk to develop other 
autoimmune diseases, in particular Grave’s disease. 
Pemphigoid gestationis tends to recur in subsequent 
pregnancies, with usually earlier onset and increasing 
severity. Only very rarely (5%) a pregnancy may be 
passed over (“skip pregnancies”).
Pathogenetically, circulating complement fixing IgG 
antibodies of the subclass IgG1 (formerly known as 
“herpes gestationis factor”) bind to a 180-kDa protein, 
BP-180 or bullous pemphigoid antigen 2 in the hemide-
smosomes of the DEJ, leading to tissue damage and blister 
formation
17. The immune response is even more highly 
restricted to the NC16A domain as it is in bullous 
pemphigoid. Of interest, the primary site of autoimmunity 
seems not to be the skin, but the placenta, as antibodies 
bind not only to the BMZ of the epidermis, but also to that 
of chorionic and amniotic epithelia, both equally of 
ectodermal origin. Aberrant expression of MHC class II 
molecules on the chorionic villi suggests an allogenic 
immune reaction to a placental matrix antigen, thought to 
be of paternal origin.
Clinical presentation
Pemphigoid gestationis presents with intense pruritus that 
occasionally may precede the manifestation of skin 
lesions. Initially, erythematous urticarial papules and 
plaques typically develop on the abdomen, character-
istically involving the umbilical region, but may spread to 
the entire skin surface. In this so-called pre-bullous stage, 
differentiation between pemphigoid gestationis and poly-
morphic eruption of pregnancy is almost impossible, both 
clinically and histopathologically. Diagnosis becomes 
clear when lesions progress to tense blisters which 
resemble those in bullous pemphigoid. Facial and mucous 
membranes are usually spared
16.
Diagnostic tests
Histopathological findings from lesional skin depend on 
the stage and severity of the disease. While the pre- 
bullous stage is characterized by edema of the upper and 
middle dermis accompanied by a predominantly perivas-
cular inflammatory infiltrate, composed of lymphocytes, 
histiocytes, and a variable number of eosinophils, the 
bullous stage reveals subepidermal blistering that, ultra 
structurally, may be located to the lamina lucida of the 
DEJ
16.
Direct immunofluorescence of perilesional skin, the gold 
standard in the diagnosis of pemphigoid gestationis, 
shows linear C3 deposition along the DEJ in 100% of 
cases and additional IgG deposition in 30%. Depending 
on the technique applied, circulating IgG antibodies in the 
patient’s serum may be detected by indirect immuno-
fluorescence in 30∼100% of cases, binding to the roof of 
the artificial cleft on salt-split skin. Antibody levels may 
also be monitored using modern ELISA and immunoblot 
techniques and show a good correlation with disease 
activity
16,17.
Course and fetal prognosis
The natural course of pemphigoid gestationis is character-
ized by exacerbations and remissions during pregnancy, 
with frequent improvement in late pregnancy followed by 
a flare-up at the time of delivery (75% of patients). After 
delivery, the lesions usually resolve within weeks to 
months but may recur with menstruation and hormonal 
contraception. Rarely, severe courses with persistence of 
skin lesions over several years may occur. Fetal prognosis Dermatoses of Pregnancy
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Fig. 1. Comparison of the two most common dermatoses of pregnancy: polymorphic eruption of pregnancy and atopic eruption of
pregnancy. Polymorphic eruption of pregnancy in a primigravida at 40 weeks gestation: Severely itchy, dark red, urticated striae distensae
are present on the abdomen, typically sparing the umbilical region (A, B). Small urticated papules with a perilesional vasospastic
halo also spread to the adjacent thighs (C).
is generally good but there is an increase in prematurity 
and small-for-date babies. Only recently, it could be 
shown that this risk correlates with disease severity, as 
represented by early onset and blister formation, and not 
with corticosteroid treatment, as has been repeatedly 
speculated before
18. Due to a passive transfer of 
antibodies from the mother to the fetus, about 10% of 
newborns may develop mild skin lesions which resolve 
spontaneously within days to weeks
16.
Treatment
Treatment depends on the stage and severity of the 
disease and aims to control pruritus and to prevent blister 
formation. Only in cases of mild pre-blistering pem-
phigoid, topical corticosteroids with or without oral 
antihistamines may be sufficient
16. All other cases require 
systemic corticosteroids (prednisolone, usually started at a 
dose of 0.5∼1 mg/kg/day) which are considered safe in 
pregnancy
19,20. When the disease improves, the dose can 
usually be reduced, but should be increased in time to 
prevent the common flare at delivery. Cases unresponsive to 
systemic corticosteroid treatment may benefit from 
immunoapheresis
21. After delivery, if necessary, the full range 
of immunosuppressive treatment may be administered.
POLYMORPHIC ERUPTION OF PREGNAN-
CY (SYNONYMS: PRURITIC URTICARIAL 
PAPULES AND PLAQUES OF PREGNANCY 
(PUPPP), TOXAEMIC RASH OF PREGNAN-
CY, TOXIC ERYTHEMA OF PREGNANCY, 
LATE-ONSET PRURIGO OF PREGNANCY)
Polymorphic eruption of pregnancy is a benign, self- 
limited pruritic inflammatory disorder that usually affects 
primigravidae in the last weeks of pregnancy or 
immediately postpartum (15%)
22. Its incidence is about 
1:160 pregnancies and the condition is associated with 
excessive maternal weight gain and multiple pregnan-
cies
22,23.
The pathogenesis of polymorphic eruption of pregnancy 
remains unclear. The main theories proposed by now 
focus on abdominal distension, hormonal and immuno-
logical factors
24. The fact that polymorphic eruption of 
pregnancy starts within striae distensae at the time of 
greatest abdominal distension favors connective tissue 
damage due to overstretching to play a central role. The 
increase of CD1a cells in the inflammatory infiltrate could 
confirm the theory that previously inert structures develop 
antigenic character, thus triggering the inflammatory 
process. Hormonal and immunological changes have not 
definitively been shown to play a role; nor has an 
association with increased birth weight or male sex of the 
newborn been confirmed
12,22.CM Ambros-Rudolph
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Clinical presentation
Polymorphic eruption of pregnancy typically starts on the 
abdomen, within the striae distensae, with severely 
pruritic urticarial papules that coalesce into plaques, 
spreading to the buttocks and proximal thighs (Fig. 1). 
Often the eruption remains located to these sites but can 
quickly generalize in severe cases. In contrast to 
pemphigoid gestationis, the sparing of the umbilical 
region is a characteristic finding. Later-on, morphology 
becomes more polymorphic, and vesicles (1∼2 mm in 
size; never bullae), widespread non-urticated erythema, 
targetoid and eczematous lesions develop in half of 
patients. The rash usually resolves within 4∼6 weeks, 
independent of delivery
22.
Diagnostic tests
Histopathology is non-specific and varies with the stage of 
disease. Besides of a superficial to mid-dermal perivas-
cular lymphohistiocytic infiltrate intermingled with eosin-
ophils, early biopsies show a prominent dermal edema, 
while later biopsies reveal frequent epidermal changes 
including spongiosis, hyper- and parakeratosis. Direct and 
indirect immunofluorescence investigations are essentially 
negative in polymorphic eruption of pregnancy.
Course and fetal prognosis
Maternal and fetal prognosis is unimpaired and there is no 
cutaneous involvement of the newborn
23. Lesions are 
self-limited and the disease tends not to recur; the 
exception being multiple pregnancies, when both earlier 
presentation and manifestation in a subsequent pregnancy 
may occur.
Treatment
Symptomatic treatment with topical corticosteroids with or 
without antihistamines is usually sufficient to control 
pruritus and skin lesions. In severe generalized cases, a 
short course of systemic corticosteroids (prednisolone, 40
∼60 mg/day, for a few days in tapering doses) may be 
necessary and is usually very effective
23.
INTRAHEPATIC CHOLESTASIS OF PREG-
NANCY (SYNONYMS: OBSTETRIC CHOLE-
STASIS, CHOLESTASIS OF PREGNANCY, 
JAUNDICE OF PREGNANCY, PRURITUS/ 
PRURIGO GRAVIDARUM)
Intrahepatic cholestasis of pregnancy is a reversible form 
of hormonally triggered cholestasis that typically develops 
in genetically predisposed individuals in late pregnancy. 
In contrast to the other dermatoses of pregnancy, it 
presents with pruritus and exclusively secondary skin 
lesions due to scratching. The incidence of intrahepatic 
cholestasis of pregnancy shows a striking geographical 
pattern; while its prevalence in Middle Europe is around 
0.2∼2.4%, it is particularly frequent in Scandinavia and 
South America, with highest rates in Chile (15∼28%)
25. 
Intrahepatic cholestasis of pregnancy runs in families and 
tends to recur in subsequent pregnancies (45∼70%)
25,26.
Pathogenetically, there is a defect in the excretion of bile 
salts resulting in elevated bile acids in the serum. This 
leads to severe pruritus in the mother, and, as toxic bile 
acids can pass into fetal circulation, may have deleterious 
effects on the fetus due to acute placental anoxia and 
cardiac depression. The reason for this defect seems to be 
multifactorial with genetic, hormonal, and exogenous 
factors being involved
25. Endemic clustering and familial 
occurrence has pointed towards a genetic background; 
recently, mutations of certain genes encoding for transport 
proteins necessary for bile excretion (e.g., the ABCB4 
[MDR 3] gene) have been identified in some intrahepatic 
cholestasis of pregnancy patients
27. With normal hormone 
levels, this defect has no clinical implications; it only 
becomes evident with highest concentrations as in late 
pregnancy and/or with hormonal contraception. Further-
more, estrogen and progesterone metabolites have been 
seen to be cholestatic themselves
28. Some authors also 
discuss additional environmental and dietary factors 
influencing the manifestation of intrahepatic cholestasis of 
pregnancy such as decreased serum selenium levels, for 
instance
29.
Clinical presentation
Intrahepatic cholestasis of pregnancy typically presents 
with sudden onset of severe pruritus that may start on 
palms and soles but quickly becomes generalized. It 
persists throughout pregnancy and may be tormenting. Of 
importance, intrahepatic cholestasis of pregnancy is not 
associated with primary skin lesions. Clinical features 
correlate with disease duration
30. When pruritus starts, the 
skin usually is completely unaffected; later-on, secondary 
skin lesions develop due to scratching and range from 
subtle excoriations to severe prurigo nodules as pruritus 
persists. Skin lesions usually involve the extensor surfaces 
of the extremities, but may also affect other sites of the 
body such as buttocks and the abdomen. Jaundice, due to 
concomitant extrahepatic cholestasis, occurs in about 
10% of patients, usually after 2∼4 weeks, complicating 
the most severe and prolonged episodes
31. These patients 
are at risk to develop steatorrhea with malabsorption of 
fat-soluble vitamins including vitamin K and potential Dermatoses of Pregnancy
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bleeding complications, as well as cholelithiasis
25.
Diagnostic tests
Histopathology is non-specific; direct and indirect immu-
nofluorescence are negative. The most sensitive indicator 
for the diagnosis of intrahepatic cholestasis of pregnancy 
is a rise of serum bile acid levels while routine liver 
function tests (including transaminases) may be normal in 
up to 30%
25,30. In healthy pregnancies, total serum bile 
acid levels are slightly higher than in non-pregnant 
women and levels up to 11.0μmol/l (normal range, 0∼6
μmol/l) are accepted as normal in late gestation
32,33. 
Hyperbilirubinemia is noted in only 10∼20%; it should 
always lead to close surveillance of prothrombin time and 
an ultrasound examination of the liver may be necessary 
to exclude cholelithiasis in such cases.
Course and fetal prognosis
The prognosis for the mother is generally good. After 
delivery, pruritus disappears spontaneously within days to 
weeks but may recur with subsequent pregnancies and 
oral contraception
25. In cases of jaundice and vitamin K 
deficiency, there is an increased risk for intra- and 
postpartum hemorrhage in both mother and child
25. 
However, the key consideration in this disease is not 
maternal pruritus but the significantly impaired fetal 
prognosis. Intrahepatic cholestasis of pregnancy is asso-
ciated with an increased risk for prematurity (19∼60%), 
intrapartal fetal distress (22∼33%) and stillbirths (1∼2%) 
which correlates with higher bile acid levels, in particular 
if exceeding 40μmol/l
25,34. Therefore, prompt diagnosis, 
specific therapy, and close obstetric monitoring as well as 
maternal counseling, in particular on the expected re-
currence in subsequent pregnancies, are essential.
Treatment
The aim of treatment is the reduction of serum bile acid 
levels in order to prolong pregnancy and reduce both fetal 
risks and maternal symptoms. Ursodeoxycholic acid 
(UDCA) is the only treatment that has been shown not 
only to reduce maternal pruritus but to also improve fetal 
prognosis
25,30,35-38. It is a naturally occurring, hydrophilic, 
non-toxic bile acid that has been successfully employed in 
Chinese medicine for over 5,000 years in treating various 
liver diseases and plays nowadays a key-role in treating 
hepatobiliary disorders. In intrahepatic cholestasis of 
pregnancy, a dose of 15 mg/kg/day or, independent of 
body weight, 1 g/day is administered either as single dose 
or divided into 2∼3 doses until delivery, when it usually 
can be stopped. With the exception of occasional mild 
diarrhea, there are no adverse effects. However, UDCA is 
not licensed for use in pregnancy, and thus requires 
special patient information (“off-label use”). Other drugs 
including antihistamines, S-adenosyl-L-methionine, dex-
amethasone, and cholestyramine could not improve fetal 
prognosis
25. Of note, cholestyramine and other bile acid 
exchange resins may contribute to malabsorption of 
vitamin K with possible consecutive bleeding compl-
ications and should therefore be avoided
39. In addition to 
UDCA treatment, close obstetric surveillance is indicated 
and includes weekly fetal cardiotocographic (CTG) 
registration at least from 34 weeks gestation on; early 
delivery as soon as lung maturity is achieved (36∼37 
weeks) is recommended by some authors
40. An inter-
disciplinary management of intrahepatic cholestasis of 
pregnancy by dermatologists, hepatologists, gynecologists, 
and pediatricians is absolutely mandatory.
ATOPIC ERUPTION OF PREGNANCY (SY-
NONYMS: PRURIGO OF PREGNANCY, PRU-
RIGO GESTATIONIS, EARLY-ONSET PRU-
RIGO OF PREGNANCY, PRURITIC FOLLI-
CULITIS OF PREGNANCY, ECZEMA IN 
PREGNANCY)
Atopic eruption of pregnancy is a benign pruritic disorder 
of pregnancy which includes eczematous and/or papular 
lesions in patients with an atopic diathesis after exclusion 
of the other dermatoses of pregnancy. It is the most 
common dermatosis in pregnancy, accounting for 50% of 
patients, starts usually early, in 75% before the third 
trimester, and tends to recur in subsequent pregnancies 
due to the atopic background
3.
The pathogenesis of AEP is thought to be triggered by 
pregnancy-specific immunological changes; a reduced 
cellular immunity and reduced production of Th1 
cytokines (IL-2, interferon gamma, IL-12) stands in contrast 
to the dominant humoral immunity and increased secret-
ion of Th2 cytokines (IL-4, IL-10)
41. Thus, the exacerbation 
of pre-existing atopic dermatitis as well as the first 
manifestation of atopic skin changes can be explained by 
a dominant Th2 immune response that is typical for 
pregnancy.
Clinical presentation
20% of patients suffer from an exacerbation of pre-existing 
atopic dermatitis with a typical clinical picture. The 
remaining 80% experience atopic skin changes for the 
first time ever or after a long remission (for example, since 
childhood). Of these, two-thirds present with widespread 
eczematous changes (so-called E-type AEP) often affecting 
typical atopic sites such as face, neck, décolleté, and the CM Ambros-Rudolph
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Fig. 2. Comparison of the two most common dermatoses of pregnancy: polymorphic eruption of pregnancy and atopic eruption of
pregnancy. Atopic eruption of pregnancy in a primigravida at 22 weeks gestation: A discrete small papular rash involves the abdomen 
(A) as well as other common atopic sites such as the neck (B) and the flexural aspects of the upper extremities (C). Presence of
severe xerosis and other atopic minor features as well as absence of striae distensae are clues to diagnosis.
flexural surfaces of the extremities, while one-third have 
papular lesions (P-type AEP)
3. The latter include small 
erythematous papules disseminated on trunk and limbs 
(Fig. 2), as well as typical prurigo nodules, mostly located 
on the shins and arms. A key-finding is the often severe 
dryness of the skin and frequent atopic “minor features” 
according to Hanifin and Rajka
42.
Diagnostic tests
Histopathology is non-specific and varies with the clinical 
type and stage of the disease. Direct and indirect immuno-
fluorescence are negative. Laboratory tests may reveal 
elevated serum IgE levels in 20∼70%
3.
Course and prognosis
Maternal prognosis is good even in severe cases as skin 
lesions usually respond quickly to therapy; recurrence in 
subsequent pregnancies is common. Fetal prognosis is 
unaffected, but there might be a risk of developing atopic 
skin changes in the infant, later-on.
Treatment
Basic treatment together with topical corticosteroids for 
several days will usually lead to quick improvement of 
skin lesions. Severe cases may require a short course of 
systemic corticosteroids and antihistamines; phototherapy 
(UVB) is a safe additional tool, particularly for severe cases 
in early pregnancy.
GENERAL CONSIDERATIONS FOR TREAT-
MENT DURING PREGNANCY
Topical treatment
Basic therapy using emollients adapted to the skin’s state 
is essential and may contain urea (3∼10%) and anti-
pruritic additives such as menthol and polidocanol that 
are considered safe in pregnancy. Additional drying of the 
skin from washing, bathing or showering can be avoided 
by using mild, non-alkaline synthetic detergents capable 
of replacing lipids as well as showering or bath oils. 
During pregnancy, mild (face, intertriginous areas) or 
moderate (rest of body) topical corticosteroids may be 
applied, preferably the new, substituted products includ-
ing methylprednisolone aceponate and mometasone 
furoate. Potent corticosteroids and uncontrolled long-term 
use should be avoided
43.
Systemic treatment
When systemic corticosteroid treatment is necessary in 
pregnancy, also non-halogenated corticosteroids should 
be administered. In the placenta, cortisol, prednisone and 
prednisolone are inactivated enzymatically (mother:child 
=10:1), but not betamethasone and dexamethasone. 
Prednisolone is the corticosteroid of choice in pregnancy. 
The usual initial dose is 0.5∼2 mg/kg/day depending on 
nature and severity of the disease. A maintenance dose 
should not exceed 10∼15 mg/day in the first trimester, as 
a slightly increased risk for cleft lips/cleft palates can 
otherwise not be excluded. In treating dermatoses of 
pregnancy corticosteroids are usually used only as a 
short-time therapy (＜4 weeks), so that side effects need Dermatoses of Pregnancy
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Fig. 3. Algorithm for the management of pruritus in pregnancy
3. ICP: intrahepatic cholestasis of pregnancy, AEP: atopic eruption of 
pregnancy, PEP: polymorphic eruption of pregnancy, PG: pemphigoid gestationis, AD: atopic dermatitis, IMF: immunofluorescence, 
H&E: histopathology, LAB: laboratory findings, DEJ: dermo-epidermal junction. 
not be expected. In rare cases with high-dose therapy over 
many weeks, fetal growth should be monitored by 
ultrasound. Should this therapy be continued up to 
delivery, possible adrenal insufficiency of the newborn 
must be kept in mind and treated accordingly. If systemic 
antihistamines are needed during pregnancy, older 
substances (dimethindene, clemastine, pheniramine) are 
preferable due to the greater experience with their use. 
This is especially valid for the first trimester. If a non- 
sedating antihistamine is required, loratadine and cetir-
izine can be administered in the second and third 
trimester
19,20.
Algorithmic approach to the pregnant patient with 
pruritus
Pruritus in pregnancy should never be neglected and 
always lead to an exact work-up of the patient. Pruritus is 
the leading symptom of the specific dermatoses of 
pregnancy, but may also be associated with dermatoses 
that coincide by chance with pregnancy (e.g., pityriasis 
rosea, cutaneous infections, urticaria) and, in a first step, 
must be ruled out. In a second step, the four specific 
dermatoses of pregnancy need to be discriminated. A 
retrospective analysis of a large patient collective revealed 
the following significant differences helpful in differential 
diagnosis (Table 3)
3. Primigravidae and multiple gestation 
pregnancies were particularly frequent in patients with 
polymorphic eruption of pregnancy and a history of 
previous pregnancies affected with similar skin changes 
was typically given in patients with intrahepatic chole-
stasis of pregnancy. While pemphigoid gestationis, poly-
morphic eruption of pregnancy and intrahepatic chole-
stasis of pregnancy characteristically presented in late 
pregnancy, atopic eruption or pregnancy started signifi-
cantly earlier, and onset before the third trimester 
occurred in 75% of patients. Abdominal involvement of CM Ambros-Rudolph
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skin lesions was stereotypical for pemphigoid gestationis 
and polymorphic eruption of pregnancy, whereas predo-
minant affection of the extremities was observed in 
patients with intrahepatic cholestasis of pregnancy, 
compared to equal involvement of trunk and limbs in 
patients with atopic eruption of pregnancy. Intrahepatic 
cholestasis of pregnancy was the only disease in that 
pruritus was the sole presenting symptom, followed by 
exclusively secondary skin lesions in all patients. Based on 
these findings, an algorithm (Fig. 3) was developed that 
may facilitate discrimination of the various pruritic 
dermatoses in pregnancy and points to appropriate 
diagnostic and therapeutic measures.
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